Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin conjugating enzyme E2 V2 pseudogene 2 (UBE2V2P2) is a pseudogene, meaning it is a DNA sequence similar to protein-coding ubiquitin conjugating enzyme E2 V2 (UBE2V2), but it does not encode a functional protein product and has no known biological or therapeutic relevance. Pseudogenes typically arise from gene duplication or retrotransposition followed by accumulation of disabling mutations, rendering them transcriptionally or translationally inactive. Key clarification: If you are seeking information about a true, functional ubiquitin conjugating enzyme, you likely mean UBE2V2, an E2 ubiquitin-conjugating enzyme involved in post-translational modification of proteins via ubiquitination[2]. The suffix "P2" denotes a pseudogene variant and is not a therapeutic or functional target. Summary judgment: UBE2V2P2 is not a functional molecular target and should not be classified as such. There is nothing to suggest clinical, experimental, or molecular relevance beyond being a gene relic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin conjugating enzyme E2 V2 pseudogene 2 (UBE2V2P2).